Patent · US Active

Polymorphic forms of Afatinib free base and Afatinib dimaleate

US11390612B2 · kind B2 · utility

0Cited by

7References

17Claims

0Family size

Assignee

Fresenius Kabi Oncology Ltd. · IN

Inventors

Walter Cabri · Sant Celoni, ES
Saswata Lahiri · Sindhar, IN
Bhuwan Bhaskar Mishra · Manesar, IN
Abul Azim · Barwala, IN
Nilendu Panda · Barwala, IN
Poli Reddy Bhavanam · Sindhar, IN
Krishanu Ray · Barwala, IN
Nikunj Shambhubhai Kachhadia · Manesar, IN
Kumber Singh · Sidhauli, IN

Key dates

Filing date	Oct 1, 2020
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Oct 1, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.